Abbott pays $170 million for PanGenetics' anti-NGF antibody
This article was originally published in Scrip
Abbott will pay $170 million up front to acquire a Phase I nerve growth factor (NGF) antibody from the Dutch antibody company PanGenetics. The deal, which is expected to close by the end of this year, also allows for a further $20 million in future milestone payments to PanGenetics.
You may also be interested in...
David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.